Skip to main content

Featured

Rental Property Expenses Canadians Forget to Claim (2026 Guide)

  Published: April 2026 | Reading time: 9 min | Category: Real Estate, Tax Savings, Personal Finance Owning a rental property in Canada comes with a surprisingly generous set of tax deductions — but most landlords only claim the obvious ones. Mortgage interest, property taxes, insurance. Done. What they miss is often worth thousands of dollars in additional deductions every single year. If you own a rental property in Ontario (or anywhere in Canada), this guide walks through every legitimate expense category the CRA allows — including the ones your accountant may not have mentioned. Why This Matters More Than You Think Rental income in Canada is taxed as regular income — meaning at your full marginal rate. At Ontario's combined federal and provincial rates, landlords earning $100,000–$150,000 total income are paying 43% on every dollar of net rental profit. Every $1,000 in legitimate deductions you miss costs you approximately $430 in real taxes . A landlord who forget...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment